Fifteen weeks after its approval in Dec. 2013, approximately 7,100 prescriptions were written per week for Sovaldi, compared to approximately 2,270 prescriptions written per week 15 weeks after competitor Hepatitis C treatment drug Incivek was approved in 2011.
Peter Costa, a Wells Fargo Securities analyst, estimated Hepatitis C treatments will cost the 10 biggest publicly traded payers $798 million more than they did in 2013, according to the report.
Sovaldi recently made headlines calling attention to its hefty price tag, costing $1,000 per pill and $84,000 for a 12-week treatment.
Payers are feeling the strain of this drug, as it currently has no rivals, and it is experiencing optimal results, according to the report. The drug guarantees a 90 percent success rate for patients.
Rhonda Greenapple, a consultant for pharmaceutical companies seeking drug reimbursement, said in the report there is nothing for payers to do until more Hepatitis C treatments are approved and become available.
More Articles on Pharmaceuticals:
Baxter to Create Global Biopharmaceutical, Medical Product Companies
Shire Pharmaceuticals Recalls VPRIV
OxyContin Manufacturer Creates Tamper-Resistant Hydrocodone Drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
